Author:
Wang Zhenyu,Zhang Huiyuan,Shi Minghao,Yu Yang,Wang Hao,Cao Wen-Ming,Zhao Yanling,Zhang Hong
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Stagg, J. & Allard, B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Therapeutic advances in medical oncology 5, 169–181 (2013).
2. Lakhani, S. R. Cancer, I. A. f. R. o. & Organization, W. H. WHO classification of tumours of the breast. (International Agency for Research on Cancer, 2012).
3. Figueroa-Magalhaes, M. C., Jelovac, D., Connolly, R. M. & Wolff, A. C. Treatment of HER2-positive breast cancer. Breast 23, 128–136 (2014).
4. Martin, S. et al. RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors. Current cancer drug targets 11, 976 (2011).
5. Gradishar, W. J. et al. Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 14, 324–354 (2016).
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献